MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients

Phase 1
Completed
Conditions
Advanced Malignant Solid Tumors
Interventions
First Posted Date
2008-08-05
Last Posted Date
2017-08-02
Lead Sponsor
Pfizer
Target Recruit Count
16
Registration Number
NCT00728468
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

🇺🇸

South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Phase 1
Completed
Conditions
Neoplasm Metastasis
Carcinoma, Non-Small Cell
Interventions
First Posted Date
2008-08-05
Last Posted Date
2024-04-22
Lead Sponsor
Pfizer
Target Recruit Count
74
Registration Number
NCT00728390
Locations
🇪🇸

Pfizer Investigational Site, Madrid, Spain

A Study In Patients With Advanced Solid Tumor

Phase 1
Completed
Conditions
Neoplasms
Interventions
First Posted Date
2008-08-01
Last Posted Date
2012-05-23
Lead Sponsor
Pfizer
Target Recruit Count
6
Registration Number
NCT00726752
Locations
🇯🇵

Pfizer Investigational Site, Kobe-shi, Hyogo-ken, Japan

An Open-Label Safety Study Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain

Phase 3
Completed
Conditions
Pain, Postoperative
Interventions
Drug: DIC075V (intravenous diclofenac sodium)
First Posted Date
2008-07-31
Last Posted Date
2021-10-13
Lead Sponsor
Pfizer
Target Recruit Count
1050
Registration Number
NCT00726388
Locations
🇺🇸

Staten Island University Hospital, Staten Island, New York, United States

🇺🇸

UPMC-St. Margaret's Hospital, Pittsburgh, Pennsylvania, United States

🇺🇸

Tulane Univ. Medical Center, New Orleans, Louisiana, United States

and more 41 locations

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Phase 1
Completed
Conditions
Lymphoma, B-Cell
Interventions
Drug: Inotuzumab Ozogamicin (CMC-544)
First Posted Date
2008-07-30
Last Posted Date
2019-03-15
Lead Sponsor
Pfizer
Target Recruit Count
10
Registration Number
NCT00724971
Locations
🇯🇵

Nagoya Daini Red Cross Hospital, Aichi, Japan

🇯🇵

Tokai University Hospital, Kanagawa, Japan

🇯🇵

National Cancer Center Hospital, Tokyo, Japan

and more 1 locations

PF-04191834 Single Dose Bronchodilatory Study In Asthma.

Phase 2
Completed
Conditions
Asthma
Interventions
First Posted Date
2008-07-28
Last Posted Date
2013-02-01
Lead Sponsor
Pfizer
Target Recruit Count
15
Registration Number
NCT00723021
Locations
🇺🇸

Pfizer Investigational Site, Omaha, Nebraska, United States

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Biological: PF-04360365 0.5 mg/kg
Biological: PF-04360365 1 mg/kg
Drug: Placebo
Biological: PF-04360365 3 mg/kg
Biological: PF-04360365 8.5 mg/kg
Biological: PF-04360365 0.1 mg/kg
First Posted Date
2008-07-25
Last Posted Date
2022-11-07
Lead Sponsor
Pfizer
Target Recruit Count
198
Registration Number
NCT00722046
Locations
🇬🇧

The Shalbourne Suite, Swindon, Wiltshire, United Kingdom

🇬🇧

Kingshill Research Centre, Swindon, Wiltshire, United Kingdom

🇺🇸

Dedicated Phase 1, Phoenix, Arizona, United States

and more 38 locations

A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers

Phase 1
Completed
Conditions
Insomnia
Interventions
First Posted Date
2008-07-25
Last Posted Date
2011-02-04
Lead Sponsor
Pfizer
Target Recruit Count
6
Registration Number
NCT00722306
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2008-07-24
Last Posted Date
2019-11-04
Lead Sponsor
Pfizer
Target Recruit Count
177
Registration Number
NCT00721409
Locations
🇺🇸

Central Hematology Oncology Medical group Inc., Alhambra, California, United States

🇺🇸

TORI -US Central Administration (Regulatory Management), Los Angeles, California, United States

🇺🇸

TORI -US Central Administration, Los Angeles, California, United States

and more 87 locations

A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections

Completed
Conditions
Systemic Fungal Infections
Interventions
First Posted Date
2008-07-24
Last Posted Date
2011-01-10
Lead Sponsor
Pfizer
Target Recruit Count
23
Registration Number
NCT00721578
Locations
🇮🇳

Pfizer Investigational Site, New Delhi, India

© Copyright 2025. All Rights Reserved by MedPath